Resultados da pesquisa - Rod Ramchandren

  • A mostrar 1 - 2 resultados de 2
Refinar resultados
  1. 1
    886MO Health-related quality of life (HRQoL) from KEYNOTE-204: A phase III, randomized, open-label study of pembrolizumab (pembro) vs brentuximab vedotin (BV) in relapsed or refractory classical Hodgkin lymphoma (R/R cHL)

    886MO Health-related quality of life (HRQoL) from KEYNOTE-204: A phase III, randomized, open-label study of pembrolizumab (pembro) vs brentuximab vedotin (BV) in relapsed or refrac... Por Pier Luigi Zinzani, Rod Ramchandren, Armando Santoro, Ewa Paszkiewicz‐Kozik, Robin Gasiorowski, Nathalie A. Johnson, José Salvador Rodrigues de Oliveira, Valéria Buccheri, Guilherme Fleury Perini, Michael Dickinson, Andrew McDonald, Muhi̇t Özcan, Naohiro Sekiguchi, Monika Raut, Ying Zhu, Akash Nahar, Patricia Marinello, John Kuruvilla

    Publicado em 2020
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  2. 2
    HEALTH‐RELATED QUALITY OF LIFE AMONG PATIENTS WITH RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA (R/R CHL) IN A PHASE 3 STUDY OF PEMBROLIZUMAB VERSUS BRENTUXIMAB VEDOTIN

    HEALTH‐RELATED QUALITY OF LIFE AMONG PATIENTS WITH RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA (R/R CHL) IN A PHASE 3 STUDY OF PEMBROLIZUMAB VERSUS BRENTUXIMAB VEDOTIN Por Pier Luigi Zinzani, Monika Raut, Todd L. Saretsky, Rod Ramchandren, Armando Santoro, Ewa Paszkiewicz‐Kozik, Robin Gasiorowski, Nathalie A. Johnson, José Salvador Rodrigues de Oliveira, Valéria Buccheri, Guilherme Fleury Perini, Michael Dickinson, Andrew McDonald, Muhi̇t Özcan, Naohiro Sekiguchi, Hilde Giezek, Akash Nahar, John Kuruvilla

    Publicado em 2021
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:

Ferramentas de pesquisa: